Viewing nowCombinationRivika Tablet 5/20 mg
Olmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Hanook Prime Pharmaceutical Co., Ltd.

MFDS item code 201406170 · Approved 2014.12.31 · Insurance code 663606550
Treatment of essential hypertension not controlled with monotherapy
This medication is used for patients with essential hypertension whose blood pressure is not adequately controlled by monotherapy with Amlodipine or Olmesartan medoxomil. Essential hypertension is a condition where blood pressure is abnormally high, increasing the risk of cardiovascular diseases; this medication helps effectively control blood pressure. Amlodipine dilates blood vessels to lower blood pressure, while Olmesartan medoxomil, an angiotensin II receptor blocker, relaxes vessel tension. It is used when adequate blood pressure control is difficult with either component alone, assisting in stabilizing blood pressure. Thus, this medication is a safe and effective treatment option for hypertension.
Administer 1 tablet of this drug once daily with water, regardless of meals. It is recommended, if possible, to take it at the same time each day (e.g., in the morning). Before administering this drug, it is recommended that the dose of the individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using an individual component, switching directly to this drug may be considered. The maximum dose of this drug is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of 2 weeks or longer, taking the patient's blood pressure response into consideration. The recommended doses are as follows: - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ○ Patients with renal impairment: This drug has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this drug is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients receiving dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ○ Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while monitoring their condition closely. ○ Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be monitored closely. This drug should not be administered to patients with severe hepatic impairment. (See section 2, Patients who should not receive this drug, under Precautions for Use.) ○ Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in elderly patients.
○ Children: The safety and efficacy of this drug in pediatric patients under 18 years of age have not been established.
This medication may cause serious harm to the fetus and newborn if taken during pregnancy, especially in the second and third trimesters; therefore, it should be discontinued immediately upon confirmation of pregnancy. Patients with allergies to this medication's active ingredients or similar classes of drugs, those who are pregnant or breastfeeding, individuals with severe liver disease or heart valve diseases, patients undergoing kidney dialysis, those in shock, and certain diabetic patients should not take this medication. Patients with low blood pressure due to dehydration or salt deficiency, patients at risk of rapidly dropping blood pressure due to sudden vasodilation, individuals with severe heart diseases, patients with compromised kidney function, and those with reduced liver function should use this medication with caution and have their conditions closely monitored at the treatment's onset. Side effects may include dizziness, headache, low blood pressure, swelling, indigestion, skin rash, among others; if symptoms are severe or persistent, consult a doctor. Especially, since potassium levels in the blood can increase, routine blood tests should be carried out to check potassium levels if taken with potassium-containing medications. Women planning pregnancy or who are pregnant are recommended to transition to other treatments with proven safety instead of this medication, and breastfeeding mothers may need to stop breastfeeding or discontinue the medication due to potential adverse reactions in the infant. Safety and efficacy in children or adolescents under 18 years of age have not been established, thus it is not recommended. Elderly patients may have decreased kidney and liver function, so it is advisable to start with a low dose and carefully adjust the dosage. In cases of overdose, severe hypotension and problems with cardiac function may occur due to vasodilation; immediate hospitalization and monitoring of blood pressure and cardiac status are necessary. This medication should be stored in a sealed container, avoiding moisture, heat, and direct sunlight, out of reach of children, and should not be transferred to another container. Additionally, taking this medication with grapefruit juice can increase blood pressure-lowering effects, so it is advisable to avoid. This medication may interact with several other drugs, so if taking other medications, it is essential to notify a doctor or pharmacist.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air and moisture exposure at room temperature between 1°C and 30°C. Storing in this way can help maintain the medication's effectiveness for a longer duration.
White round film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Hanook Prime Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.